Last reviewed · How we verify
NCT06802328
Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients
trial testing Foralumab TZLS-401 50 µg in Non-Active Secondary Progressive Multiple Sclerosis. Available.
Quick facts
| Lead sponsor | Tiziana Life Sciences LTD |
|---|---|
| Status | AVAILABLE |
| Study type | EXPANDED_ACCESS |
| Sites | 1 location across United States |
Drugs / interventions tested
- Foralumab TZLS-401 50 µg — full drug profile →
Conditions studied
- Non-Active Secondary Progressive Multiple Sclerosis — all drugs for Non-Active Secondary Progressive Multiple Sclerosis →
Sponsor
Tiziana Life Sciences LTD — full company profile →
Who can join
Adults 25 to 75, any sex, with Non-Active Secondary Progressive Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, intermediate-size patient population expanded access treatment study utilizing 1 dose level of nasal Foralumab (50 µg/dosing day) with the possibility of increasing to 100 µg/dosing day. The goal of this expanded access clinical trial is to evaluate safety, tolerability, and immune effects of intranasal Foralumab in non-active secondary progressive multiple sclerosis patients. The primary objective is to treat patients who have failed current available therapy. Participants will visit the clinic for testing and follow-up every cycle (3 weeks) while administering the medication at home if able three times weekly.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Nasal Foralumab for the Treatment of Progression Independent of Relapses in Patients With Nonactive Secondary Progressive Multiple Sclerosis
Chitnis T, Singhal T, Zurawski J, Saraceno T, et al · · 2026
Verify or expand the search:
- PubMed search for NCT06802328
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-Active Secondary Progressive Multiple Sclerosis
Currently open trials in the same condition.
- NCT06890923 — Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis · Phase 2 · recruiting
Other Tiziana Life Sciences LTD trials
Trials by the same sponsor.
- NCT06868628 — A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) · Phase 2 · recruiting
- NCT06890923 — Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis · Phase 2 · recruiting
- NCT05028946 — A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease · Phase 1 · withdrawn
- NCT04983446 — In-patient COVID-19 Study of Intranasal Foralumab · Phase 2 · withdrawn
- NCT06879067 — Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06802328 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tiziana Life Sciences LTD
- Last refreshed: 6 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06802328.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing